The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: The OLCA study

Diabetes and Vascular Disease Research

Volumn 9, Issue 4, 2012, Pages 280-286

  Daikuhara, Hiroyuki ^a   Kikuchi, Fumi ^b   Ishida, Toshihiko ^b  

^a Sakaide City Hospital   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

haemoglobin A1c; Heart rate; morning blood pressure; sympathetic nerve activity; urinary albumin

Indexed keywords

ALBUMIN; AMLODIPINE; AZELNIDIPINE; CANDESARTAN; GLUCOSE; HEMOGLOBIN A1C; OLMESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

AGED; ALBUMINURIA; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866650068     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112447310     Document Type: Article

References (18)

1. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009 ; 32: 3-107
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ; 289: 2560-2572
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 ; 28: 1462-1536
4. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 ; 359: 2417-2428
5. Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 ; 56: 77-85
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010 ; 55: 399-407
7. Koike H, Konse T, Sada T, et al. Olmesartan medoxomil, a novel potent angiotensin II blocker. Annu Rep Sankyo Res Lab. 2003 ; 55: 1-91
8. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003 ; 26: 201-208
9. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007 ; 57: 698-704
10. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007 ; 333: 321-326
11. Ogawa S, Mori T, Nako K, et al. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008 ; 31: 1147-1155
12. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003 ; 23: 419-430
13. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005 ; 111: 1777-1783
14. Ogihara T, Saruta T, Shimada K, et al. A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertens Res. 2009 ; 32: 1148-1154
15. Iwai M, Li HS, Chen R, et al. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther. 2006 ; 319: 1081-1087
16. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997 ; 15: 3-17
17. Nagaya T, Yoshida H, Takahashi H, et al. Resting heart rate and blood pressure, independent of each other, proportionally raise the risk for type-2 diabetes mellitus. Int J Epidemiol. 2010 ; 39: 215-222
18. Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007 ; 56: 1727-1730